RedHill Biopharma to sell ADSs in public offering via Nomura, Roth

Proceeds will fund research and development of therapeutic candidates

By Toni Weeks

San Luis Obispo, Calif., July 14 – RedHill Biopharma Ltd. said it plans an underwritten public offering of its American Depository Shares. The deal will have a 30-day, 15% over-allotment option.

Each ADS represents 10 ordinary shares.

Nomura and Roth Capital Partners are the joint bookrunning managers. MLV & Co. and H.C. Wainwright & Co. are co-managers.

Proceeds will be used for research and development-related purposes in connection with the company’s therapeutic candidates and for potential acquisitions and general corporate purposes.

The Tel Aviv-based biopharmaceutical company focuses on late-clinical-stage, orally administered small-molecule drugs for inflammatory and gastrointestinal diseases, including cancers.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.